

CORPORATE FACT SHEET



As of March 31, 2010

OFFICES

45 Moulton Street
Cambridge, MA 02138
e-mail: info@curis.com
URL: www.curis.com
Phone: 617-503-6500
Fax: 617-503-6501

BUSINESS

Drug Development with a small molecule cancer focus

FOUNDED

2000

OWNERSHIP

Publicly traded on NASDAQ Global Market ("CRIS")

SHARES

75.6 million basic shares outstanding
89.3 fully diluted shares outstanding

EMPLOYEES

Approximately 40

COLLABORATIONS

- (1) Genentech: Hedgehog Antagonist (Cancer)
- (2) Genentech: Wnt signaling pathway (Cancer)
- (3) Debiopharm: Hsp90 (Cancer)

TRANSFER AGENT

BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015
URL: www.bnymellon.com/shareowner/isd
Phone: 877-810-2248

Please see Curis' Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings that we periodically make with the Securities & Exchange Commission for additional information on the company and its status based on filing date.

MANAGEMENT TEAM

Daniel R. Passeri, President and
Chief Executive Officer

Michael P. Gray, Chief Operating and
Chief Financial Officer

Changgeng Qian, Ph.D., M.D., Senior Vice President,
Discovery and Preclinical Development

Mitchell Keegan, Ph.D., Vice President, Drug Development

Mark W. Noel, Vice President, Technology Management and
Intellectual Property

BOARD OF DIRECTORS

James R. McNab, Jr. - Chairman of the Board

Susan B. Bayh

Joseph M. Davie, Ph.D., M.D.

Martyn D. Greenacre

Kenneth I Kaitin, Ph.D.

Daniel R. Passeri

Marc Rubin, M.D.

James R. Tobin